Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccinationLouis P Garrison
Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
J Infect Dis 204:S124-32. 2011
..Funders need to prioritize their scarce research and development resources. This article demonstrates the usefulness of cost-effectiveness analysis to support these decisions...
Estimating the costs of induced abortion in Uganda: a model-based analysisJoseph B Babigumira
Global Medicines Program, Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA
BMC Public Health 11:904. 2011
..These abortions, which are usually unsafe, lead to a high rate of severe complications and use of substantial, scarce healthcare resources. This study was performed to estimate the costs associated with induced abortions in Uganda...
- BMI trajectories among the severely obese: results from an electronic medical record population
Edwin S Wong
Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
Obesity (Silver Spring) 20:2107-12. 2012
..Our results also suggest that once the 35 BMI threshold is reached, individuals will continue to remain severely obese, especially at younger ages...
- Examining the BMI-mortality relationship using fractional polynomials
Edwin S Wong
Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
BMC Med Res Methodol 11:175. 2011
..This approach was then compared against other commonly used regression models...
- Potential cost-effectiveness of universal access to modern contraceptives in Uganda
Joseph B Babigumira
Global Medicines Program, Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, United States of America
PLoS ONE 7:e30735. 2012
....
Systematic review of comparative effectiveness data for oncology orphan drugsMindy M Cheng
Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
Am J Manag Care 18:47-62. 2012
..To systematically assess clinical and economic evidence for oncology orphan drugs marketed in the United States and to highlight the challenges and opportunities for evidence development within this pharmaceutical category...
- Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program
Joseph B Babigumira
Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
J Infect Dis 204:S116-23. 2011
..Before an elimination program is initiated, it is important to consider its potential economic impact, including its cost-effectiveness...
- Preference values associated with stage III colon cancer and adjuvant chemotherapy
Jennie H Best
University of Washington, Seattle, WA, USA
Qual Life Res 19:391-400. 2010
..To elicit preference values for health states associated with Stage III colon cancer (CRC) and to explore the effect of neuropathy associated with current adjuvant treatment...
- Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda
Joseph B Babigumira
Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, Washington, United States of America
PLoS ONE 6:e18193. 2011
..The PRP was started to reduce workforce shortages and optimize patient care by substituting pharmacy visits for SOC involving monthly physician visits for accessing antiretroviral medicines...
- Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer
Jennie H Best
Department of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195, USA
Expert Rev Pharmacoecon Outcomes Res 10:103-14. 2010
..e., providing good value for money) but, furthermore, would actually be cost saving in the majority of country settings...
- Paying for personalized care: cancer biomarkers and comparative effectiveness
Rahber Thariani
Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
Mol Oncol 6:260-6. 2012
..Evidence of comparative effectiveness can also help support value-based reimbursement of cancer biomarkers and treatment strategies as means of paying for personalized medicine...
- Stakeholder perspectives on a risk-benefit framework for genetic testing
Joshua A Roth
Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
Public Health Genomics 14:59-67. 2011
..The meeting's findings emphasize the potential utility of risk-benefit analysis in genetic test evaluation, and highlight key areas for future research and stakeholder consensus-building...
- Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
Louis P Garrison
Department of Pharmacy, University of Washington, Seattle, Washington, USA
Cancer 110:489-98. 2007
..A cost-effectiveness analysis was performed to assess clinical and economic implications of adding trastuzumab to adjuvant chemotherapy, based upon joint analysis of NSABP B-31 and NCCTG N9831 trials...
- The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision
David R Flum
University of Washington Schools of Medicine, Pharmacy and Public Health, Seattle, WA, USA
Ann Surg 254:860-5. 2011
..To determine the impact of the Centers for Medicare and Medicaid Services' (CMS) bariatric surgery national coverage decision (NCD) on the use, safety, and cost of care CMS beneficiaries...
- Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score
Sean D Sullivan
University of Washington, Seattle, WA 98195 7630, USA
J Med Econ 14:609-16. 2011
..The first approach identified high risk patients using impaired fasting glucose (IFG). The second approach used the PreDx Diabetes Risk Score (DRS) to further stratify IFG patients into high-risk and moderate-risk groups...
- The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)
William B Wong
Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
Contemp Clin Trials 33:1117-23. 2012
..The objective of this study was to assess the value of research of the RxPONDER study, an ongoing comparative effectiveness RCT designed to evaluate a 21-gene profile in early stage, node-positive breast cancer...
- Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
Josh J Carlson
Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195 7630, United States
Health Policy 96:179-90. 2010
..To identify, categorize and examine performance-based health outcomes reimbursement schemes for medical technology...
- Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy
Gregory F Guzauskas
Center for Genomics and Healthcare Equality, University of Washington, Seattle, Washington, USA
Genet Med 15:84-7. 2013
..We evaluated genetic services stakeholder opinions on the potential usefulness of decision-analytic modeling to inform coverage decisions, and asked them to identify genetic tests for decision-analytic modeling studies...
- Innovation in diagnostic imaging services: assessing the potential for value-based reimbursement
Louis P Garrison
Department of Pharmacy, University of Washington, Seattle, USA
Acad Radiol 18:1109-14. 2011
..The authors examine how and whether value-based reimbursement for diagnostic imaging services might better reward innovation explicitly for expected improvements in health and economic outcomes...
- The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment
Mindy M Cheng
University of Washington, Seattle, WA 98195, USA
J Med Econ 13:193-202. 2010
..To critically evaluate published cost-effectiveness studies of novel drug products requiring less-frequent medication dosing compared to conventional formulations of the same drug substance...
- The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
Josh J Carlson
School of Pharmacy, University of Washington, Seattle, WA 98195, USA
Value Health 12:20-7. 2009
..The objective of this study was to evaluate the potential cost-utility of implementing epidermal growth factor receptor (EGFR) testing before initiating second-line therapy for advanced refractory non-small-cell lung cancer (NSCLC)...
- Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda
Joseph B Babigumira
Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
BMC Health Serv Res 9:192. 2009
..We estimated the potential impact of task-shifting on costs of antiretroviral therapy (ART) and physician supply in Uganda. The study was performed at the Infectious Diseases Institute (IDI) clinic, a large urban HIV clinic...
- The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer
Louis P Garrison
Department of Pharmacy, University of Washington, Health Sciences Building, Seattle, WA 98195 7630, USA
Value Health 12:1118-23. 2009
....
- Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II
Louis P Garrison
University of Washington, Seattle, WA 98195 7630, USA
Value Health 13:8-13. 2010
....
- Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows?
Louis P Garrison
Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
Pharmacoeconomics 28:855-65. 2010
..All said, it would seem that BRA and CER should be neither strangers nor strange bedfellows, but may need to be coaxed into being bedfellows...
- Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis
Louis P Garrison
Department of Pharmacy, University of Washington, Seattle, USA
Health Aff (Millwood) 26:684-95. 2007
....
